FGFR inhibitor · small molecule
derazantinib
1 active trials across 2 of our biomarkers, targeting FGFR1-3. Not approved for any biomarker on marked.bio yet.
Also known as ARQ 087.
Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.
Biomarkers
| Biomarker | Active trials | All trials | Furthest active phase |
|---|---|---|---|
| FGFR2 fusion or rearrangement | 1 | 4 | Phase 2 |
| FGFR3 alteration (mutation or fusion) | 0 | 2 | – |
Trials
1 of 4 trials shown
-
Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements
Histologically documented diagnosis of non-resectable iCCA with positively confirmed FGFR2 fusion/rearrangement via NGS-Analysis.
FGFR2 fusion or rearrangementIntrahepatic Cholangiocarcinoma
-
Derazantinib and Atezolizumab in Patients With Urothelial Cancer
Documented central FGFR genetic aberration (FGFR1, FGFR2, or FGFR3 mutations / short variants and rearrangements / fusions) (Note
FGFR3 alteration (mutation or fusion)FGFR2 fusion or rearrangementUrothelial Carcinoma
-
Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarci…
FGFR2 fusion or rearrangementIntrahepatic Cholangiocarcinoma, Combined Hepatocellular and Cholangiocarcinoma
-
Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
…ents eligible for enrollment in the Expanded Cohort must have documented and/or confirmed FGFR genetic aberrations, including iCCA with FGFR2 gene fusion.
FGFR3 alteration (mutation or fusion)FGFR2 fusion or rearrangementSolid Tumor
No trials match these filters.